LH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.56B

+6.94%

3.939

+14.16%

3.50B

+4.63%

4.104

+6.88%

3.68B

+4.27%

4.637

+6.59%

Estimates Revision

The market is revising Downward the revenue expectations for Labcorp Holdings Inc. (LH) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by -9.35%.

Revenue Estimates for FY2025

Revise Downward

-0.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.13%

In Past 3 Month

Stock Price

Go Down

-9.35%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

270.00

Averages

307.00

High

342.00

Current: 0.000

Low

270.00

Averages

307.00

High

342.00

Piper Sandler

David Westenberg

Neutral

downgrade

$280 -> $270

2025-11-10

Reason

Piper Sandler

David Westenberg

Price Target

$280 -> $270

2025-11-10

downgrade

Neutral

Reason

Piper Sandler analyst David Westenberg lowered the firm's price target on Labcorp to $270 from $280 following quarterly results. The firm keeps a Neutral rating on the shares.

JPMorgan

NULL -> Overweight

maintain

$291 -> $317

2025-11-07

Reason

JPMorgan

Price Target

$291 -> $317

2025-11-07

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Labcorp to $317 from $291 and keeps an Overweight rating on the shares. The firm updated the company's model.

UBS

Kevin Caliendo

Buy

downgrade

$325 -> $320

2025-10-29

Reason

UBS

Kevin Caliendo

Price Target

$325 -> $320

2025-10-29

downgrade

Buy

Reason

UBS analyst Kevin Caliendo lowered the firm's price target on Labcorp to $320 from $325 and keeps a Buy rating on the shares.

Baird

Outperform -> Outperform

downgrade

$313 -> $304

2025-10-29

Reason

Baird

Price Target

$313 -> $304

2025-10-29

downgrade

Outperform -> Outperform

Reason

Baird lowered the firm's price target on Labcorp to $304 from $313 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.

Mizuho

Ann Hynes

Outperform

maintain

$285 -> $320

2025-10-17

Reason

Mizuho

Ann Hynes

Price Target

$285 -> $320

2025-10-17

maintain

Outperform

Reason

Mizuho analyst Ann Hynes raised the firm's price target on Labcorp to $320 from $285 and keeps an Outperform rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also "cautiously optimistic" that contract research organization trends have bottomed.

UBS

Buy

maintain

$305 -> $325

2025-10-17

Reason

UBS

Price Target

$305 -> $325

2025-10-17

maintain

Buy

Reason

UBS raised the firm's price target on Labcorp to $325 from $305 and keeps a Buy rating on the shares.

Valuation Metrics

The current forward P/E ratio for Labcorp Holdings Inc (LH.N) is 14.66, compared to its 5-year average forward P/E of 14.64. For a more detailed relative valuation and DCF analysis to assess Labcorp Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.64

Current PE

14.66

Overvalued PE

16.44

Undervalued PE

12.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.71

Current EV/EBITDA

10.65

Overvalued EV/EBITDA

11.83

Undervalued EV/EBITDA

9.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.56

Current PS

1.44

Overvalued PS

1.75

Undervalued PS

1.36

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 676.52% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LH News & Events

Events Timeline

No data

News

8.5

01-08PRnewswire

PinnedNAMSA Acquires Labcorp's Early Development Medical Device Testing Business

8.0

01-09Barron's

Clinical Labs Aim to Prevent Upcoming Medicare Reductions

8.5

01-08Newsfilter

NAMSA Acquires Labcorp's Early Development Medical Device Testing Business

People Also Watch

Frequently Asked Questions

What is Labcorp Holdings Inc (LH) stock price today?

The current price of LH is 251.81 USD — it has decreased -1.12 % in the last trading day.

What is Labcorp Holdings Inc (LH)'s business?

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development, medical device and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.

What is the price predicton of LH Stock?

What is Labcorp Holdings Inc (LH)'s revenue for the last quarter?

Labcorp Holdings Inc revenue for the last quarter amounts to 3.56B USD, increased 8.58 % YoY.

What is Labcorp Holdings Inc (LH)'s earnings per share (EPS) for the last quarter?

Labcorp Holdings Inc. EPS for the last quarter amounts to 3.12 USD, increased 55.22 % YoY.

What changes have occurred in the market's expectations for Labcorp Holdings Inc (LH)'s fundamentals?

How many employees does Labcorp Holdings Inc (LH). have?

Labcorp Holdings Inc (LH) has 70000 emplpoyees as of January 10 2026.

What is Labcorp Holdings Inc (LH) market cap?

Today LH has the market capitalization of 20.88B USD.